EVA Pharma takes Egyptian commercialisation rights to BeiGene’s oncology portfolio

The licensed market is Egypt, so the transaction is African on the face of the primary source: an Egyptian manufacturer-distributor obtains commercial rights to a Chinese-origin oncology portfolio for the Egyptian market.


Coverage: The Meridian legal market record (editorial).

The licensed market is Egypt, so the transaction is African on the face of the primary source: an Egyptian manufacturer-distributor obtains commercial rights to a Chinese-origin oncology portfolio for the Egyptian market.

Record ID TX-AFR-2025-0010
Record type Commercial IP transaction
Transaction type Trade mark licence, In-licensing
IP rights trade mark, regulatory data
Status Announced
Qualifying date 2025-03-26
Sector Life sciences · Pharmaceuticals – oncology
African markets Egypt
Licensed territory Egypt.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • EVA Pharma (Egypt): licensee
  • BeiGene: licensor

Key terms

  • Interest: licence (commercialisation); Exclusivity: not stated by source; Territorial scope: Egypt; Field of use: Oncology

Sources

  1. EVA Pharma and BeiGene Announce a Strategic Partnership to Bring Innovative Oncology Therapies to Patients in Egypt, EVA Pharma, 2025-03-26

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.